Comparative effectiveness of odronextamab monotherapy <i>versus</i> real-world systemic therapies in R/R follicular lymphoma
To contextualize results from the single-arm ELM-2 study of odronextamab (CD20 × CD3 bispecific antibody) in relapsed/refractory (R/R) follicular lymphoma (FL) (<i>N</i> = 128), a <i>post-hoc</i> comparison was conducted <i>versus</i> third-line or later systemic therapies used in the real world (3L + RWST) in FLORA, a multinational, noninterventional study (<i>N</i> = 83; 100 lines of therapy). After weighting, objective response rate (80.5 <i>vs.</i> 52.7%; odds ratio [OR], 3.75 [95% CI, 1.98-7.11]), complete response rate (73.4 <i>vs.</i> 33.6%; OR, 5.39 [95% CI, 2.76-10.53]), median (months) progression-free survival (20.7 <i>vs.</i> 11.5; hazard ratio [HR], 0.76 [95% CI, 0.46-1.24]), event-free survival (19.5 <i>vs.</i> 7.6; HR, 0.52 [95% CI, 0.36-0.77]), overall survival (not reached <i>vs.</i> 26.2; HR, 0.60 [95% CI, 0.37-0.97]), and time to next treatment or death (40.4 <i>vs.</i> 9.7; HR, 0.49 [95% CI, 0.33-0.72]) favored odronextamab <i>versus</i> 3L + RWST. Despite FLORA's limited sample size, these data further support odronextamab monotherapy for 3L + R/R FL.
Authors
- J. Harnett
- Anit Bajwa
- Soyeon Kim (ORCID: https://orcid.org/0000-0002-9736-5668)
- Siddhesh Kamat
- Jenny M. H. Chen (ORCID: https://orcid.org/0000-0002-0575-3699)
- Christian Hampp (ORCID: https://orcid.org/0000-0002-1094-6364)
- Liza Mastikhina (ORCID: https://orcid.org/0000-0001-8412-143X)
- Ruben Hermans
- Joy Wang (ORCID: https://orcid.org/0000-0003-2045-2963)
- Jessica J. Jalbert (ORCID: https://orcid.org/0000-0001-8566-6466)
- Gerd Rippin
- Katharina Prochazka (ORCID: https://orcid.org/0000-0002-7201-5987)
- Julie E. Park (ORCID: https://orcid.org/0000-0002-8054-5443)
- J.R. Radford
- Aafia Chaudhry
- Yingxin Xu
- Emmanuel Bachy
- Srikanth Ambati
- John Kuruvilla
- Hung Kam Cheung
- Nicolas Martinez-Calle
- Richard Patt
- Hesham Mohamed
- Qiufei Ma
- Stefano Luminari
- Ángel Serna
- William Townsend
- Sylvie Tiso
- Catherine Thieblemont
- Gandhi Laurent Damaj
Institutions
- Université Claude Bernard Lyon 1 (FR)
- University of Modena and Reggio Emilia (IT)
- Nottingham University Hospitals NHS Trust (GB)
- Regeneron (United States) (US)
- Medical University of Graz (AT)
- Université Paris Cité (FR)
- Manchester Academic Health Science Centre (GB)
- Cancer Research UK (GB)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Hospital (KR)
- IQVIA (United Kingdom) (GB)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Vall d'Hebron Hospital Universitari (ES)
- The Christie NHS Foundation Trust (GB)
- Institut de Recherche en Hématologie et Transplantation (FR)
- Hôpital Saint-Louis (FR)
- CRUK Lung Cancer Centre of Excellence (GB)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- University College London (GB)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1080/10428194.2026.2619500
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00